PUBLICATIONS & ABSTRACTS: CLINICAL EVIDENCE

100s of extensive peer reviewed publications and studies utilizing MammaPrint + BluePrint have observed benefits from treatment in the following areas of clinical utility:


Scientific evidence for clinical utility.

By continually expanding and strengthening our database of proven research including 20+ years of clinical validation and 200+ research collaborations, we have gained widespread trust in the precision, accuracy and quality of our MammaPrint® and BluePrint® test suite.

Evidence

Gene expression associated with lymphovascular invasion and genomic risk in early-stage breast cancer

PUBLICATION: ASCO 2021 Authors Nina D’Abreo1,2, Abhinav Rohatgi1,2, Douglas Kanter Marks1,2, Heather M. Kling3, Josien Haan4, William Audeh3, FLEX Investigators Group5 Background Lymphovascular invasion (LVI), the passage of carcinoma cells through lymphatic and blood vessels, is an important early step in metastasis; however, LVI is excluded from most breast Read More

High concordance of 70‐gene recurrence risk signature and 80‐gene molecular subtyping signature between core needle biopsy and surgical resection specimens in early‐stage breast cancer

Publication: J Surg Oncol. 2022;125:596–602. Authors: Jennifer A. Crozier, MD et al. Title: High concordance of 70‐gene recurrence risk signature and 80‐gene molecular subtyping signature between core needle biopsy and surgical resection specimens in early‐stage breast cancer Abstract Background: With increased neoadjuvant therapy recommendations for early‐stage breast cancer patients Read More

MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles (FLEX): A real-world dataset and investigator-initiated protocols in ESBC

  Publication: St. Gallen Authors: Jennifer A. Crozier, Lisa Blumencranz, Miranda Kleijn, Heather Kling, Amy M. Truitt, Darina Proni, Christine Finn, William Audeh, Bastiaan van der Baan, FLEX Investigators’ Group Background: The personalized management of early-stage breast cancers is enhanced by the ability of genomic signatures to stratify tumors into Read More

5-year distant metastasis-free survival outcomes on the pre-operative use of MammaPrint and BluePrint for neoadjuvant decisions in the NBREaST II trial

Publication: St. Gallen Authors: E. Göker, M.P. Hendriks, M. van Tilburg, A. Barcaru, L. Mittempergher, A. van Egmond, M. Kleijn and D. Generali Background: The 80-gene signature BluePrint® (BP) discriminates between three distinctive molecular subtypes: Luminal-type, HER2-type and Basal-type.1 Combined with the 70-gene signature MammaPrint® (MP), BP can further stratify Read More

Pathologic Complete Response (pCR) Rates According to MammaPrint and BluePrint Results are Consistent Among Pre- and Post-Menopausal Patients

  Publication: Miami Breast  Authors Pat Whitworth, James V Pellicane, Jr., Paul Baron, Peter Beitsch, Laura Lee, Angela Mislowsky, Carrie Dul, Paul Richards, Mark Gittleman, Stephanie Akbari, Shiyu Wang, Andrea Menicucci, Lisa Blumencranz, William Audeh, NBRST Investigators Group. Background Increased use of multi-gene expression profiling has enabled refinement Read More